Evaluating Immune-Related Adverse Events Using PRO-CTCAE in a Phase II Study of Ipilimumab for Hormone-Sensitive Prostate Cancer. - de Almeida, Daniel Vargas P.; Anderson, Justine M.; Danila, Daniel C.; Morris, Michael J.; Slovin, Susan F.; Abida, Wassim; Cohn, Erica D.; Baser, Raymond E.; Scher, Howard I.; Autio, Karen A. (Journal of Immunotherapy & Precision Oncology, 2023)